Headquartered in Burnaby, BC Fiscal year ends December NASDAQ: XENE xenon-pharma.com
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of therapeutics for neurologic and psychiatric disorders. The company's lead molecule, azetukalner, is a novel KV7 potassium channel opener in late-stage clinical development for the treatment of epilepsy (focal onset seizures and primary generalized tonic-clonic seizures), major depressive disorder, and bipolar depression. Xenon leverages expertise in human genetics, ion channel biology, and novel chemistries to develop selective ion channel modulators. Beyond azetukalner, the company is advancing an early-stage portfolio of potassium and sodium channel modulators, including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain. Xenon also has a collaboration with Neurocrine Biosciences on NBI-921355, a selective NaV1.2/NaV1.6 inhibitor for epilepsy. The company is pre-revenue, with its first NDA submission for azetukalner in focal onset seizures targeted for Q3 2026. Xenon trades on Nasdaq under the ticker XENE. Updated
Two small-cap biotech names made serious noise today. Xenon Pharmaceuticals (XENE) is trading at $62.76, up 49.6% today, while Relmada Therapeutics (RLMD) sits at $7.17, also up 61.1% Both moves were absolutely eye-popping, but…
The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names…
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of therapeutics for neurologic and psychiatric disorders.
The Wall Street consensus 12-month price target for XENE is $72.42. XENE price prediction →
